International Lung Cancer Summit· @LungSummit · X·· 2 days agoScore70
Body · original
Tomorrow at #ESMO26: the primary analysis of DeLLphi-305, tarlatamab plus durvalumab vs durvalumab alone as 1L maintenance in ES-SCLC, from our faculty member Jacob Sands (@sands_jacob). LBA3, 17:18, Hall 6.
Calendar file: https://lungsummit.org/wp-content/uploads/2026/09/esmo2026.ics
What would you ask him? @myESMO
137 views · 3 likes · 2 reposts · 0 replies
Conference abstracts
LBA3matched by Presidential Symposium I
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgSource: International Lung Cancer Summit · x.com